# Title

 Food and Drugs. PART 3â€”PRODUCT JURISDICTION


# ID

 CFR-2018-title21-vol1.Pt. 3


# Structured Analysis Summary

| Type        | Values                                                                                                |
|:------------|:------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'within', 'more than', 'not to exceed', 'exceed', 'greater']                               |
| Duration    | ['30.0 day', '60.0 day', '15.0 day']                                                                  |
| Condition   | ['where', 'as soon as', 'if', 'when', 'subject to']                                                   |
| Entities    | ['Scope', 'Chemical', 'Food', 'Request', 'Rockville, MD', 'Research', 'Product', 'Purpose', 'Effect'] |
| Date        | ['2018-09-01']                                                                                        |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                        |
|:--------------|:-------------------------------------------------------------------------------------------------------------------------------|
| within        | specifying how FDA will determine the organizational component within FDA designated to have primary jurisdiction for the      |
| more than     | most cases, the need to receive approvals from more than  one FDA component for such combination products.                     |
| more than     | Because combination products are comprised of  more than one type of regulated article (biological product, device,            |
| more than     | Because combination products are comprised of  more than one type of regulated article (biological product, device,            |
| within        | achieve its primary intended purposes through chemical action within or on the body of man or other                            |
| greater       | which one mode of action will provide a greater contribution than any other mode of action to                                  |
| before        | designated agency component identified in the intercenter agreement before submitting an application of premarket review or to |
| before        | designation of the agency component with primary jurisdiction before  submitting the application.                              |
| before        | a sponsor should file a request for designation before filing any application for premarket review, whether an                 |
| exceed        | The request for designation must not  exceed 15 pages, including attachments, and must set forth:                              |
| within        | request for designation will be reviewed for completeness within  5 working days of receipt.                                   |
| within        | product at issue, and any consulting agency components. within                                                                 |
| within        | officer has not issued a letter of designation within 60 days of the filing date of a                                          |
| within        | jurisdiction officer to reconsider the decision by filing, within 15 days of receipt of the letter of                          |
| within        | review and act on the request in writing within  15 days of its receipt.                                                       |
| not to exceed | an additional 30 days to submit written objections, not to exceed 15 pages, to the proposed change, and shall                  |
| within        | for the proposed change in designated agency component. within                                                                 |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                            |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 60.0 day   | (b) Within 60 days of the filing date of a request for designation, the product jurisdiction officer will issue a letter of designation to the sponsor, with copies to the centers, specifying the agency component designated to have primary jurisdiction for the premarket review and regulation of the product at issue, and any consulting agency components. |
| 60.0 day   | If the product jurisdiction officer has not issued a letter of designation within 60 days of the filing date of a request for designation, the sponsor's recommendation of the center with primary jurisdiction, in accordance with &#167;&#8201;3.7(c)(3), shall become the designated agency component.                                                          |
| 15.0 day   | (c) Request for reconsideration by sponsor: If the sponsor disagrees with the designation, it may request the product jurisdiction officer to reconsider the decision by filing, within 15 days of receipt of the letter of designation, a written request for reconsideration not exceeding 5 pages.                                                              |
| 15.0 day   | The product jurisdiction officer shall review and act on the request in writing within 15 days of its receipt.                                                                                                                                                                                                                                                     |
| 30.0 day   | A sponsor shall be given 30 days written notice of any proposed nonconsensual change in designated agency component.                                                                                                                                                                                                                                               |
| 30.0 day   | The sponsor may request an additional 30 days to submit written objections, not to exceed 15 pages, to the proposed change, and shall be granted, upon request, a timely meeting with the product jurisdiction officer and appropriate center officials.                                                                                                           |
| 30.0 day   | Within 30 days of receipt of the sponsor's written objections, the product jurisdiction officer shall issue to the sponsor, with copies to appropriate center officials, a written determination setting forth a statement of reasons for the proposed change in designated agency component.                                                                      |


## Condition

| Condition   | Context                                                                                                                            |
|:------------|:-----------------------------------------------------------------------------------------------------------------------------------|
| where       | jurisdiction for any drug, device, or biological product where  such jurisdiction is unclear or in dispute.                        |
| where       | approved individually specified drug, device, or biological product where both are required to achieve the intended use,           |
| where       | approved individually specified drug, device, or biological product where both are required to achieve the intended use,           |
| where       | approved individually specified drug, device, or biological product where both are required to achieve the intended use,           |
| if          | part has a biological product mode of action if it acts by means of a virus, therapeutic                                           |
| if          | constituent part has a device mode of action if it meets the definition of device contained in                                     |
| if          | constituent part has a drug mode of action if it meets the definition of drug contained in                                         |
| where       | (a) Any combination product, or (b) Any product where the agency component with primary jurisdiction is unclear                    |
| where       | by a guidance document or for a product where the agency component with primary jurisdiction is unclear                            |
| where       | by an intercenter agreement; or (2) Any product where the agency component with primary jurisdiction is unclear                    |
| when        | for marketing approval or a required investigational notice. when                                                                  |
| as soon as  | are encouraged to file a request for designation as soon as there is sufficient information for the agency to                      |
| if          | (i) Class if ication, name of the product and all component                                                                        |
| subject to  | received premarket approval, is marketed as not being subject to premarket approval, or has received an investigational exemption, |
| where       | to the attention of the product jurisdiction officer. where                                                                        |
| if          | written request for reconsideration not exceeding 5 pages. if                                                                      |
| subject to  | of designation constitutes an agency determination that is subject to change only as provided in paragraph (b) of                  |


## Entities

| Entities      | Context                                                                                                                            |
|:--------------|:-----------------------------------------------------------------------------------------------------------------------------------|
| Food          | Food  and Drugs.                                                                                                                   |
| Purpose       | Purpose .                                                                                                                          |
| Research      | component means the Center for Biologics Evaluation and Research , the Center for Devices and Radiological Health,                 |
| Research      | component means the Center for Biologics Evaluation and Research , the Center for Devices and Radiological Health,                 |
| Scope         | Scope .                                                                                                                            |
| Research      | (a)(1) The Center for Biologics Evaluation and  Research , the Center for Devices and Radiological Health,                         |
| Rockville, MD | 1061,  Rockville, MD 20852, and are entitled &#8220;Intercenter Agreement Between the                                              |
| Research      | Agreement Between the Center for Drug Evaluation and Research and the Center for Devices and Radiological Health;&#8221;           |
| Product       | Product  jurisdiction officer.                                                                                                     |
| Request       | Request  for designation.                                                                                                          |
| Chemical      | (v)  Chemical , physical, or biological composition; (vi) Status and                                                               |
| Request       | its mailing cover should be plainly marked &#8220; Request  for Designation.&#8221; Concurrent submissions of electronic copies of |
| Effect        | Effect  of letter of designation.                                                                                                  |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                               |
|:-----------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2018-09-01 | (c) The designation of one agency component as having primary jurisdiction for the premarket review and regulation of a combination product does not preclude consultations by that component with other agency components or, in appropriate cases, the requirement by FDA of separate applications. |


